Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: omalizumab Clear all
Completed Phase 4 Interventional Results available

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

NCT00555971
View directory record Official record
Conditions
Aspirin Sensitivity
Interventions
Omalizumab, placebo
Drug
Lead sponsor
David Lang
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 26, 2026, 4:08 AM EDT
Withdrawn Phase 1 Interventional

Xolair Interventional Study in ASD Patients With Comorbid Atopy

NCT04535817
View directory record Official record
Conditions
Autism Spectrum Disorder, Atopy
Interventions
Omalizumab Injection [Xolair]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 26, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

Omalizumab Weight-Based Dosing Efficacy Trial

NCT06943534
View directory record Official record
Conditions
Allergies, Food Allergy
Interventions
5mg/kg omalizumab injection, 15mg/kg omalizumab injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model

NCT01040598
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Omalizumab
Biological
Lead sponsor
O & O Alpan LLC
Other
Eligibility
12 Years to 76 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Springfield, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Immune Dysfunction in Allergic Asthma

NCT00189228
View directory record Official record
Conditions
Asthma
Interventions
Xolair
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 26, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

Omalizumab Before Onset of Exacerbations

NCT05332067
View directory record Official record
Conditions
Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

NCT00180011
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
DiMango, Emily, M.D.
Individual
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy, Omalizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 26, 2026, 4:08 AM EDT
Terminated Early Phase 1 Interventional

Gastrointestinal STRING Test With Oral Immunotherapy

NCT04943744
View directory record Official record
Conditions
Eosinophilic Disorder, Food Allergy
Interventions
Entero-tracker, omalizumab, dupliumab
Device · Biological
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy

NCT00329381
View directory record Official record
Conditions
Asthma
Interventions
Xolair
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

NCT00123630
View directory record Official record
Conditions
Esophagitis
Interventions
omalizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

NCT01678092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
omalizumab
Biological
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 26, 2026, 4:08 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958
View directory record Official record
Conditions
Moderate-to-severe Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Rolling Hills Estates, California • Denver, Colorado • Pembroke Pines, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 26, 2026, 4:08 AM EDT
Not listed No phase listed Observational

The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy

NCT01776177
View directory record Official record
Conditions
Allergic Asthma
Interventions
Not listed
Lead sponsor
Joseph D. Diaz, MD
Industry
Eligibility
12 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT03280550
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Roseville, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction

NCT02266355
View directory record Official record
Conditions
Colon Cancer
Interventions
Omalizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Xolair in Patients With Chronic Sinusitis

NCT00117611
View directory record Official record
Conditions
Sinusitis
Interventions
Anti-IgE antibody omalizumab or placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

NCT04180488
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab SAR231893, Placebo, non sedating H1-antihistamine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 80 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 26, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

NCT01287117
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 26, 2026, 4:08 AM EDT